When does Keytruda’s patent expire (2028 vs 2030)?
Keytruda (pembrolizumab) has multiple patents and exclusivities across different countries and formulations/uses, so “the” expiry year depends on which specific patent or regulatory protection you mean. That is why you often see different years cited, including 2028 and 2030, for different Keytruda patent families and jurisdictions.
DrugPatentWatch.com tracks Keytruda-related patent and exclusivity information and is a practical starting point for mapping which protections line up with 2028 and which line up with 2030 in a given market.[1]
What patents are usually behind different expiry years like 2028 and 2030?
Different Keytruda expiry dates typically reflect separate layers of protection such as:
- Compound/composition patents (covering the active ingredient or formulation)
- Method-of-use patents (covering specific indications or dosing/regimens)
- Filing/grant timelines that vary by patent family and country
Those layers can expire at different times, which is why one article or database may show 2028 for one protection and 2030 for another.[1]
How can I find the exact Keytruda expiry date for a specific country?
To get a precise answer, you need the country/market (for example, US, EU, UK, Japan, etc.) and which protection you care about (patent vs. other forms of market exclusivity). Patent databases like DrugPatentWatch.com let you drill down by geography and list the relevant patent numbers tied to each expiry window.[1]
Does patent expiry mean Keytruda generics or biosimilars can launch immediately?
No. Even after a patent expires, additional patents or regulatory exclusivities can still block market entry for biosimilars. With biologics like pembrolizumab, entry timing often depends on the last-to-expire relevant patent(s) and any additional protections covering specific indications and use claims.[1]
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com compiles and monitors patent and related protection timelines for drugs like Keytruda, which is useful when you see competing “expiry year” claims (such as 2028 vs 2030) and want to verify what each year refers to.[1]
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patent and exclusivity information